Skip to main content
AmigoFish

Episode 167: Pancreatic Cancer Series, Pt. 2 – Resectable Disease

From The Fellow on Call: The Heme/Onc Podcast ·

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

This week our pancreatic cancer series moves from diagnosis to management, starting with resectable disease. Using the case of a 68-year-old man with a 2.8 cm adenocarcinoma of the pancreatic head, we define what "resectable" actually means, review the operation and the goal of an R0 resection, and explain why surgery alone is never enough. We then trace the adjuvant story from ESPAC-1 and CONKO-001 to today's two standards, modified FOLFIRINOX (PRODIGE 24) and gemcitabine-capecitabine (ESPAC-4), before taking on the surgery-first versus neoadjuvant debate (NORPACT-1, PREOPANC, SWOG S1505), the question of preoperative biliary stenting, and what is coming next.

As always, if you haven't listened to part 1 of this series, start there first.

This episode is sponsored by Primum! As questions of oncology experts (including pancreatic cancer) free! To learn more and to sign up for your free account, visit Primum.co/fellows

** Want to review the show notes for this episode and others? Check out our website.

Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!

Twitter: @TheFellowOnCall

Instagram: @TheFellowOnCall

Listen in on: Apple Podcast, Spotify, and Youtube

Back to The Fellow on Call: The Heme/Onc Podcast · Report a problem